Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $958M | $-264M | $-288M | $-193M | -47.8% | 432.1% | -38.1% |
| 2024 | $180M | $-450M | $-466M | $-462M | -61.8% | - | 24.7% |
| 2023 | $0M | $-360M | $-374M | $-326M | -92.2% | - | 26.5% |
| 2022 | $0M | $-291M | $-295M | $-225M | -149.6% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 958.40 |
| Operating Revenue | 958.40 |
| Cost Of Revenue | 56.15 |
| Gross Profit | 902.26 |
| Operating Expense | 1,202.35 |
| Research And Development | 388.52 |
| Selling General And Administration | 813.83 |
| Total Expenses | 1,258.50 |
| Operating Income | -300.10 |
| Total Operating Income As Reported | -300.10 |
| EBITDA | -264.47 |
| Normalized EBITDA | -261.69 |
| EBIT | -265.98 |
| Interest Income | 37.36 |
| Interest Expense | 22.31 |
| Net Interest Income | 15.06 |
| Other Non Operating Income Expenses | -0.46 |
| Other Income Expense | -3.24 |
| Interest Income Non Operating | 37.36 |
| Interest Expense Non Operating | 22.31 |
| Net Non Operating Interest Income Expense | 15.06 |
| Pretax Income | -288.28 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income From Continuing And Discontinued Operation | -288.28 |
| Net Income From Continuing Operation Net Minority Interest | -288.28 |
| Net Income | -288.28 |
| Net Income Common Stockholders | -288.28 |
| Net Income Including Noncontrolling Interests | -288.28 |
| Normalized Income | -285.50 |
| Diluted NI Availto Com Stockholders | -288.28 |
| Basic Average Shares | 22.43 |
| Diluted Average Shares | 22.43 |
| Reconciled Depreciation | 1.51 |
| Reconciled Cost Of Revenue | 56.15 |
| Total Unusual Items | -2.78 |
| Total Unusual Items Excluding Goodwill | -2.78 |
| Special Income Charges | -2.78 |
| Other Special Charges | 2.78 |
| General And Administrative Expense | - |
| Other Gand A | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc.this co. | MDGL | $11.4B | -39.41 | 18.85 | -47.8% | -43.53 |
| BridgeBio Pharma, Inc. | BBIO | $13.2B | -18.19 | -6.32 | 34.7% | -26.38 |
| Axsome Therapeutics, Inc. | AXSM | $11.9B | -65.03 | 134.91 | -207.5% | -70.25 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | $10.6B | -6491.00 | 22.72 | -0.3% | 65.92 |
| Cytokinetics, Incorporated |
| - |
| - |
| - |
| - |
| - |
| - |
| CYTK |
| $9.8B |
| - |
| - |
| 119.0% |
| - |
| The Ensign Group, Inc. | ENSG | $9.6B | 27.92 | 4.30 | 15.4% | 19.90 |
| ImmunityBio, Inc. | IBRX | $7.6B | -21.73 | -15.26 | 70.2% | -36.08 |
| Nuvalent, Inc. | NUVL | $7.4B | -17.46 | 5.95 | -34.1% | - |
| Praxis Precision Medicines, Inc. | PRAX | $7.4B | -24.34 | 8.41 | -34.5% | -21.54 |
| Peer Median | - | -21.73 | 5.95 | 7.5% | -23.96 | |